Rare Brain Disease Treatment Trial Approved By FDA For This Company

NeuroSense Receives FDA Confirmation for PrimeC: A Potential Game Changer in ALS Treatment.

In a significant development for the medical field and especially for patients suffering from Amyotrophic Lateral Sclerosis (ALS), NeuroSense Therapeutics has received confirmation from the U.S. Food and Drug Administration (FDA) of its Chemistry, Manufacturing, and Controls (CMC) strategy for its product, PrimeC. This is a pivotal move towards the Phas…